Alumis ALMS Form 4 shows director’s funds buying common stock
Rhea-AI Filing Summary
Alumis Inc. (ALMS) director Srinivas Akkaraju reported open-market purchases of Alumis common stock made through affiliated investment funds.
On 11/17/2025, Samsara Opportunity Fund, L.P. bought 914 shares at a weighted average price of $5.51. On 11/18/2025, it purchased 102,652 shares at a weighted average of $6.05, and on 11/19/2025 it bought 137,772 shares at a weighted average of $6.56. After these transactions, the reporting person is deemed to beneficially own 517,517 shares held by Samsara Opportunity Fund, L.P. and 4,491,731 shares held by Samsara BioCapital, L.P., with beneficial ownership disclaimed except for any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 137,772 | $6.56 | $904K |
| Purchase | Common Stock | 102,652 | $6.05 | $621K |
| Purchase | Common Stock | 914 | $5.51 | $5K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.51 to $5.52 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.72 to $6.44 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.23 to $6.81 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
FAQ
What does the Alumis (ALMS) Form 4 filing report?
The Form 4 reports that director Srinivas Akkaraju disclosed recent open-market purchases of Alumis Inc. common stock through affiliated investment funds.
What does it mean that the prices are reported as weighted averages in the Alumis Form 4?
The filing states that each price is a weighted average because shares were bought in multiple trades across a price range. Detailed trade-by-trade prices are available upon request from the issuer, any security holder, or the SEC staff.